Aprea Therapeutics Q3 net loss narrows to $4.0M; cash $33.1M; ATRN-119 Phase 1 initiated

Aprea Therapeutics, Inc.

2022-Q3 EPS reported -$4.17

Net loss of $4.0M ($0.12 per share) vs $9.5M ($0.45) in Q3 2021; cash and equivalents $33.1M (down from $53.1M at Dec 2021).
R&D expenses fell to $1.1M from $6.0M due to trial close-outs and Atrin acquisition cost reductions.
Phase 1 trial of ATR inhibitor ATRN-119 opened for enrollment; expects 1-2 additional sites in Q4 2022.
WEE1 inhibitor ATRN-W1051 in preclinical stage; IND-enabling studies anticipated in Q4 2022.
APR-548 Phase 1 trial closed; no ongoing clinical trials of eprenetapopt (APR-246).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aprea Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $4.0 million, or $0.12 per share, EPS $0.12 per share.

Period: the third quarter ended September 30, 2022
Net income: Net loss was $4.0 million, or $0.12 per share
EPS: $0.12 per share
Result: reported results

Exact text from the filing

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and nine months ended September 30, 2022 and provided a business update.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-116496

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.